Updates are available Correction dated 2022-03-27

Article History

Received: 12 January 2021

Revised: 4 June 2021

Accepted: 27 July 2021

First Online: 4 August 2021

Change Date: 27 March 2022

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s00415-022-11083-1

Declarations

:

: A.B. received speaker’s honoraria and/or compensation for consulting service and/or speaking activities from Biogen, Roche, Merck, Celgene, Coloplast and Genzyme. A.F. and A.B. report no disclosures. A.C. received speaker honoraria from Biogen, Sanofi Genzyme, Teva and travel grants from Biogen, Merck, Sanofi Genzyme, Teva; advisory boards member honoraria from Biogen, Merck, Novartis, Teva. E.D. received speaking honoraria from Bayer, Biogen, Merck, Novartis, Roche, Sanofi and TEVA. G.M. received honoraria for consulting services/travel grants from Biogen, Merck Serono, Sanofi-Genzyme, Teva, Roche and Novartis. L.S. received honoraria for consulting services/travel grants from Merck, Novartis, Biogen. D.S. reports no disclosures. R.D. received speaker’s honoraria and/or compensation for consulting service and/or speaking activities from Roche, Merck, Novartis and Almirall. M.C.B. report no disclosures. M.M. has served on scientific advisory boards for Bayer Schering, Biogen, Sanofi Genzyme, Merck-Serono, Novartis, Teva, Mylan, and has received consulting and/or speaking fees, research support and travel grants from Almirall, Bayer Schering, Biogen, CSL Behring, Sanofi Genzyme, Merck Serono, Novartis, Teva, Ultragenix. He is also the principal investigator in clinical trials for Biogen, Merck Serono, Novartis, Roche, Sanofi Genzyme, CSL Behring. S.G.C. and A.Z. report no disclosures. C.G.N. received honoraria for consulting services/travel grants from Biogen, Merck Serono, Sanofi-Genzyme, Teva, Roche, Mylan and Novartis. M.S. receives research support and has received fees as the speaker from Sanofi-Aventis, Biogen, Bayer Schering and Merck. V.B. report no disclosures. FP has served on scientific Advisory Boards for Almirall, Bayer, Biogen, Celgene, Merck, Novartis, Roche, Sanofi and TEVA; he also received speaker honoraria from the same companies and research grants for his department by Biogen and Merck. Marfia Girolama Alessandra is an Advisory Board member of Biogen Idec, Genzyme, Merck-Serono, Novartis, Teva and received honoraria for speaking or consultation fees from Almirall, Bayer Schering, Biogen Idec, Merck Serono, Novartis, Sanofi-Genzyme, Teva. She is the principal investigator in clinical trials for Actelion, Biogen Idec, Merck Serono, Mitsubishi, Novartis, Roche, Sanofi-Genzyme, Teva. G.S., V.S., D.O. and G.S. report no disclosures. G.T. has received compensation for consulting services and/or speaking activities from Bayer Schering Pharma, Biogen Idec, Merck Serono, and Teva Pharmaceutical Industries; and receives research support from Biogen Idec, Merck Serono, and Fondazione Italiana Sclerosi Multipla. A.G. received honoraria for speaking and travel grants from Biogen, Sanofi-Aventis, Merck Serono, Genzyme, Teva, Bayer-Schering and Novartis.

: This study was approved by local Ethic Committees. All procedures performed in this study involving human participants were in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

: Informed consent was obtained from all individual participants included in the study.

: A signed informed consent was obtained from all participants.